nach oben

Drugs

Erschienen in:

01.07.2010 | Therapy In Practice

Drug Treatment of Hyperlipidaemia

A Guide to the Rational Use of Lipid-Lowering Drugs

verfasst von: Dr Peter P. Toth

Erschienen in: Drugs | Ausgabe 11/2010

Einloggen, um Zugang zu erhalten

Abstract

Mammalian sterol and lipid metabolism depends on a large number of highly evolved biochemical and histological processes responsible for the absorption, distribution and steady-state anabolic/catabolic handling of these substances. Lipoproteins are complex polymolecular assemblies comprising phospholipids, cholesterol and cholesterol esters, triglycerides and a variety of apolipoproteins. The primary function of lipoproteins is to facilitate the systemic distribution of sterols and lipids. Abnormalities in lipoprotein metabolism are quite common and are attributable to a large number of genetic mutations, metabolic derangements such as insulin resistance or thyroid dysfunction, and excess availability of cholesterol and fat from dietary sources. Dyslipidaemic states facilitate endothelial dysfunction and atherogenesis. Dyslipidaemia is recognized as a risk factor for cardiovascular disease in both men and women, and people of all racial and ethnic groups throughout the world. Dyslipidaemia is modifiable with dietary change and the use of medications that impact on lipid metabolism through a variety of mechanisms. Reducing atherogenic lipoprotein burden in serum is associated with significant and meaningful reductions in risk for a variety of cardiovascular endpoints, including myocardial infarction, ischaemic stroke, development of peripheral arterial disease and mortality.

This review provides an overview on how to best position lipid-lowering drugs when attempting to normalize serum lipid profiles and reduce risk for cardiovascular disease. HMG-CoA reductase inhibitors (statins) are widely accepted to be the agents of choice for reducing serum levels of low-density lipoprotein cholesterol (LDL-C) in both the primary and secondary prevention settings. Ezetimibe and bile acid sequestrants are both effective agents for reducing LDL-C, either used alone or in combination with statins. The statins, fibric acid derivatives (fibrates) and niacin raise high-density lipoprotein cholesterol to different extents depending upon genetic and metabolic background. Fibrates, niacin and omega-3 fish oils are efficacious therapies for reducing serum triglycerides. Combinations of these drugs are frequently required for normalizing mixed forms of dyslipidaemia.

Davidson MH, Toth PP. Comparative effects of lipid-lowering therapies. Prog Cardiovasc Dis 2004; 47(2): 73–104PubMedCrossRef

Toth PP. Low-density lipoprotein reduction in high-risk patients: how low do you go? Curr Atheroscler Rep 2004; 6(5): 348–52PubMedCrossRef

Tabas I. Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency. Arterioscler Thromb Vasc Biol 2005; 25(11): 2255–64PubMedCrossRef

Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 2007; 116(16): 1832–44PubMedCrossRef

Libby P. Inflammation in atherosclerosis. Nature 2002; 420(6917): 868–74PubMedCrossRef

Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009; 54(23): 2129–38PubMedCrossRef

Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285 (19): 2486–97

Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult: 2009 recommendations. Can J Cardiol 2009; 25(10): 567–79PubMedCrossRef

De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24(17): 1601–10PubMedCrossRef

10.

Boden WE, Toth PP. The evolving dyslipidemia treatment paradigm: the imperative to address residual cardiovascular disease risk beyond LDL-C. Clin Symp 2009; 59(2): 1–43

11.

Kannel WB, Castelli WP, Gordon T. Cholesterol in the prediction of atherosclerotic disease: new perspectives based on the Framingham study. Ann Intern Med 1979; 90(1): 85–91PubMed

12.

Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986; 256(20): 2823–8PubMedCrossRef

13.

Assmann G, Cullen P, Schulte H. The Munster Heart Study (PROCAM): results of follow-up at 8 years. Eur Heart J 1998; 19 Suppl. A: A2–11PubMed

14.

Benfante R. Studies of cardiovascular disease and cause-specific mortality trends in Japanese-American men living in Hawaii and risk factor comparisons with other Japanese populations in the Pacific region: a review. Hum Biol 1992; 64(6): 791–805PubMed

15.

Toth PP. Making a case for quantitative assessment of cardiovascular risk. J Clinical Lipidol 2007; 1: 234–41CrossRef

16.

Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110(2): 227–39PubMedCrossRef

17.

Smith Jr SC, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Endorsed by the National Heart, Lung, and Blood Institute [published erratum appears in Circulation 2006 Jun 6; 113 (22): e847]. Circulation 2006; 113(19): 2363–72PubMedCrossRef

18.

Toth PP. When high is low: raising low levels of high-density lipoprotein cholesterol. Curr Cardiol Rep 2008; 10(6): 488–96PubMedCrossRef

19.

Armani A, Toth PP. SPARCL: the glimmer of statins for stroke risk reduction. Curr Atheroscler Rep 2007; 9(5): 347–51PubMedCrossRef

20.

Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res 1995; 36(2): 211–28PubMed

21.

Navab M, Anantharamaiah GM, Reddy ST, et al. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation 2004; 109(25): 3215–20PubMedCrossRef

22.

Cuchel M, Rader DJ. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation 2006; 113(21): 2548–55PubMedCrossRef

23.

Heinecke JW. The HDL proteome: a marker —and perhaps mediator —of coronary artery disease. J Lipid Res 2009; 50 Suppl.: S167–71PubMedCrossRef

24.

Vaisar T, Pennathur S, Green PS, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007; 117(3): 746–56PubMedCrossRef

25.

Castelli WP. Cholesterol and lipids in the risk of coronary artery disease: the Framingham Heart Study. Can J Cardiol 1988; 4 Suppl A: 5A–10APubMed

26.

Castelli WP, Doyle JT, Gordon T, et al. HDL cholesterol and other lipids in coronary heart disease: the cooperative lipoprotein phenotyping study. Circulation 1977; 55(5): 767–72PubMedCrossRef

27.

Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989; 79(1): 8–15PubMedCrossRef

28.

Chapman MJ, Assmann G, Fruchart JC, et al. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid —a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 2004; 20(8): 1253–68PubMedCrossRef

29.

Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 western prospective studies. Circulation 2007; 115(4): 450–8PubMedCrossRef

30.

Toth PP, Dayspring TD, Pokrywka GS. Drug therapy for hypertriglyceridemia: fibrates and omega-3 fatty acids. Curr Atheroscler Rep 2009; 11(1): 71–9PubMedCrossRef

31.

Castelli WP. Epidemiology of triglycerides: a view from Framingham. Am J Cardiol 1992; 70(19): 3H–9HPubMedCrossRef

32.

Miller M, Cannon CP, Murphy SA, et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2008; 51(7): 724–30PubMedCrossRef

33.

Fruchart JC. Peroxisome proliferator-activated receptor-alpha activation and high-density lipoprotein metabolism. Am J Cardiol 2001; 88(12A): 24N–9NPubMedCrossRef

34.

Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279(20): 1615–22

35.

Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97 (15): 1440–5

36.

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344(8934): 1383–9

37.

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339 (19): 1349–57

38.

Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364(9435): 685–96PubMedCrossRef

39.

Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial —Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361(9364): 1149–58PubMedCrossRef

40.

Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359(21): 2195–207PubMedCrossRef

41.

Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360(9346): 1623–30PubMedCrossRef

42.

Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295(13): 1556–65PubMedCrossRef

43.

Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291(9): 1071–80PubMedCrossRef

44.

Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350(15): 1495–504PubMedCrossRef

45.

Cannon CP. The IDEAL cholesterol: lower is better. JAMA 2005; 294(19): 2492–4PubMedCrossRef

46.

Cannon CP, Steinberg BA, Murphy SA, et al. Metaanalysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006; 48(3): 438–45PubMedCrossRef

47.

LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352(14): 1425–35PubMedCrossRef

48.

Gibson CM, Pride YB, Hochberg CP, et al. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) substudy. J Am Coll Cardiol 2009; 54(24): 2290–5

49.

Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective metaanalysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366(9493): 1267–78PubMedCrossRef

50.

Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371(9607): 117–25PubMedCrossRef

51.

Toth PP, Davidson MH. High-dose statin therapy: benefits and safety in aggressive lipid lowering. J Fam Pract 2008; 57 (5 Suppl. High-Dose): S29–36PubMed

52.

Toth PP, Harper CR, Jacobson TA. Clinical characterization and molecular mechanisms of statin myopathy. Expert Rev Cardiovasc Ther 2008; 6(7): 955–69PubMedCrossRef

53.

Toth PP, Cadman C. Implications of recent statin trials for primary care practice. J Clin Lipidol 2007; 1: 182–90PubMedCrossRef

54.

Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002; 288(4): 462–7PubMedCrossRef

55.

Jones P. Beyond LDL-C: importance of triglycerides and non-HDL as an independent cardiovascular disease risk factor. J Am Acad Physician Assist 2008; 11: S7–19

56.

The Lipid Research Clinics Coronary Primary Prevention Trial results. I: reduction in incidence of coronary heart disease. JAMA 1984; 251(3): 351–64CrossRef

57.

Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323(19): 1289–98PubMedCrossRef

58.

Davidson MH, Toth P, Weiss S, et al. Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin Cardiol 2001; 24(6): 467–74PubMedCrossRef

59.

Knapp HH, Schrott H, Ma P, et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med 2001; 110(5): 352–60PubMedCrossRef

60.

Hunninghake D, Insull Jr W, Toth P, et al. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis 2001; 158(2): 407–16PubMedCrossRef

61.

Zieve FJ, Kalin MF, Schwartz SL, et al. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther 2007; 29(1): 74–83PubMedCrossRef

62.

Goldberg RB, Fonseca VA, Truitt KE, et al. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med 2008; 168(14): 1531–40PubMedCrossRef

63.

Fonseca VA, Rosenstock J, Wang AC, et al. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 2008; 31(8): 1479–84PubMedCrossRef

64.

Stayrook KR, Bramlett KS, Savkur RS, et al. Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology 2005; 146(3): 984–91PubMedCrossRef

65.

Musha H, Hayashi A, Kida K, et al. Gender difference in the level of high-density lipoprotein cholesterol in elderly Japanese patients with coronary artery disease. Intern Med 2006; 45(5): 241–5PubMedCrossRef

66.

Altmann SW, Davis Jr HR, Zhu LJ, et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004; 303(5661): 1201–4PubMedCrossRef

67.

Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358(14): 1431–43PubMedCrossRef

68.

Bruckert E, Giral P, Tellier P. Perspectives in cholesterol-lowering therapy: the role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption. Circulation 2003; 107(25): 3124–8PubMedCrossRef

69.

Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002; 40(12): 2125–34PubMedCrossRef

70.

Jackevicius CA, Tu JV, Ross JS, et al. Use of ezetimibe in the United States and Canada. N Engl J Med 2008; 358(17): 1819–28PubMedCrossRef

71.

Ballantyne CM, Abate N, Yuan Z, et al. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J 2005; 149(3): 464–73PubMedCrossRef

72.

Brown BG, Taylor AJ. Does ENHANCE diminish confidence in lowering LDL or in ezetimibe? N Engl J Med 2008; 358(14): 1504–7PubMedCrossRef

73.

Toth PP. Subclinical atherosclerosis: what it is, what it means and what we can do about it. Int J Clin Pract 2008; 62(8): 1246PubMedCrossRef

74.

Toth PP, Maki K. A commentary on the implications of the ENHANCE (Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression) trial: should ezetimibe move to the “back of the line” as a therapy for dyslipidemia? J Clin Lipidol 2008; 2(5): 313–7PubMedCrossRef

75.

Rossebo AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008; 359(13): 1343–56PubMedCrossRef

76.

Cannon CP, Giugliano RP, Blazing MA, et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008; 156(5): 826–32PubMedCrossRef

77.

Manninen V, Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988; 260(5): 641–51PubMedCrossRef

78.

Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001; 285(12): 1585–91PubMedCrossRef

79.

Rubins HB, Robins SJ, Collins D, et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002; 162(22): 2597–604PubMedCrossRef

80.

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000; 102 (1): 21–7

81.

Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366(9500): 1849–61PubMedCrossRef

82.

Prueksaritanont T, Zhao JJ, Ma B, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002; 301(3): 1042–51PubMedCrossRef

83.

Prueksaritanont T, Subramanian R, Fang X, et al. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos 2002; 30(5): 505–12PubMedCrossRef

84.

ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362(17): 1563–74PubMedCrossRef

85.

Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8(6): 1245–55PubMedCrossRef

86.

Lamon-Fava S, Diffenderfer MR, Barrett PH, et al. Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins. Arterioscler Thromb Vasc Biol 2008; 28(9): 1672–8PubMedCrossRef

87.

Kamanna VS, Kashyap ML. Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents? Am J Cardiol 2007; 100(11 A): S53–61PubMedCrossRef

88.

Tunaru S, Kero J, Schaub A, et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 2003; 9(3): 352–5PubMedCrossRef

89.

Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345(22): 1583–92PubMedCrossRef

90.

Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004; 110(23): 3512–7PubMedCrossRef

91.

Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin 2006; 22(11): 2243–50PubMedCrossRef

92.

Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009; 361(22): 2113–22PubMedCrossRef

93.

Mosca L, Appel LJ, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: American Heart Association scientific statement. Arterioscler Thromb Vasc Biol 2004; 24(3): e29–50PubMedCrossRef

94.

Guyton JR, Bays HE. Safety considerations with niacin therapy. Am J Cardiol 2007; 99(6A): 22–31CCrossRef

95.

Birjmohun RS, Kastelein JJ, Poldermans D, et al. Safety and tolerability of prolonged-release nicotinic acid in statin-treated patients. Curr Med Res Opin 2007; 23(7): 1707–13PubMedCrossRef

96.

Cefali EA, Simmons PD, Stanek EJ, et al. Improved control of niacin-induced flushing using an optimized once-daily, extended-release niacin formulation. Int J Clin Pharmacol Ther 2006; 44(12): 633–40PubMed

97.

Cefali EA, Simmons PD, Stanek EJ, et al. Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation. Int J Clin Pharmacol Ther 2007; 45(2): 78–88PubMed

98.

Rubenfire M; Impact of Medical Subspecialty on Patient Compliance to Treatment Study Group. Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study. Am J Cardiol 2004; 94(3): 306–11PubMedCrossRef

99.

Oberwittler H, Baccara-Dinet M. Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment. Int J Clin Pract 2006; 60(6): 707–15PubMedCrossRef

100.

Maccubbin D, Koren MJ, Davidson M, et al. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol 2009; 104(1): 74–81PubMedCrossRef

101.

Paolini JF, Mitchel YB, Reyes R, et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol 2008; 101(5): 625–30PubMedCrossRef

102.

AIM-HIGH Cholesterol Management Program. Working toward a healthy heart [online]. Available from URL: http://www.aimhigh-heart.com/background.shtml [Accessed 2010 May 27]

103.

Harper CR, Jacobson TA. Usefulness of omega-3 fatty acids and the prevention of coronary heart disease. Am J Cardiol 2005; 96(11): 1521–9PubMedCrossRef

104.

Kris-Etherton PM, Harris WS, Appel LJ; American Heart Association, Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. [published erratum appears in Circulation 2003 Jan 28; 107 (3): 512]. Circulation 2002; 106(21): 2747–57PubMedCrossRef

105.

Lee JH, O’Keefe JH, Lavie CJ, et al. Omega-3 fatty acids for cardioprotection. Mayo Clin Proc 2008; 83(3): 324–32PubMedCrossRef

106.

Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002; 105(16): 1897–903PubMedCrossRef

107.

Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007; 369(9567): 1090–8PubMedCrossRef

108.

Lovaza® prescribing information. Research Triangle Park (NC): GlaxoSmithKline, 2009 [online]. Available from URL: http://us.gsk.com/products/assets/us_lovaza.pdf [Accessed 2010 May 27]

109.

Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28(7): 1547–54PubMedCrossRef

Titel: Drug Treatment of Hyperlipidaemia
A Guide to the Rational Use of Lipid-Lowering Drugs
verfasst von: Dr Peter P. Toth
Publikationsdatum: 01.07.2010
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 11/2010
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/10898610-000000000-00000

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Drug Treatment of Hyperlipidaemia

A Guide to the Rational Use of Lipid-Lowering Drugs

Abstract

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2010

Ecallantide

Rituximab

Dapoxetine

Prophylaxis of Postoperative Endophthalmitis Following Cataract Surgery

Lapatinib

Drugs in Development for Influenza